Oxcarbazepine (All indications) updated on 04-22-2025

Childhood autism (F84.0)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9082
R31081		 Christensen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 Childhood autism (mean age almost 9 years old) during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.50 [0.06;4.51] C
excluded (control group) 		1/321   4/647 5 321
ref
S9084
R31085		 Christensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013 Childhood autism (mean age almost 9 years old) during pregnancy (anytime or not specified) population based cohort propective unexposed (general population or NOS) Adjustment: Yes 1.00 [0.10;6.90] 1/321   2,064/655,205 2,065 321
ref
Total 1 studies 1.00 [0.12;8.31] 2,065 321
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013Christensen, 2013 1 1.00[0.10; 6.90]2,0653210%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.52.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed NOS) (Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.00[0.12; 8.31]2,065321 -NAChristensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.00[0.12; 8.31]2,065321 -NAChristensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013 1 Tags Adjustment   - Yes  - Yes 1.00[0.12; 8.31]2,065321 -NAChristensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013 1 All studiesAll studies 1.00[0.12; 8.31]2,065321 -NAChristensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013 10.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9082

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.12; 8.31]2,065321 -NAChristensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.50[0.06; 4.51]5321 -NAChristensen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 10.510.01.0